within Pharmacolibrary.Drugs.ATC.J;

model J05AX18
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.94,
    Cl             = 7.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 480 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0455,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0115,
    Tlag           = 0,            
    Vdp             = 0.0425,
    k12             = 20.7,
    k21             = 20.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AX18</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Letermovir is an antiviral medication approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). It works as a CMV DNA terminase complex inhibitor and is currently approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters for healthy adult subjects, mainly following oral administration, as reported in published population pharmacokinetic studies.</p><h4>References</h4><ol><li><p>Scheuenpflug, J, et al., &amp; Rübsamen-Schaeff, H (2022). The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 11(1) 6–15. DOI:<a href=\"https://doi.org/10.1002/cpdd.1043\">10.1002/cpdd.1043</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34812580/\">https://pubmed.ncbi.nlm.nih.gov/34812580</a></p></li><li><p>Prohn, M, et al., &amp; Cho, CR (2021). Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 10(3) 255–267. DOI:<a href=\"https://doi.org/10.1002/psp4.12593\">10.1002/psp4.12593</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33440077/\">https://pubmed.ncbi.nlm.nih.gov/33440077</a></p></li><li><p>Suetsugu, K, et al., &amp; Ieiri, I (2024). Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation. <i>Clinical pharmacokinetics</i> 63(7) 945–964. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01392-1\">10.1007/s40262-024-01392-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39012618/\">https://pubmed.ncbi.nlm.nih.gov/39012618</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AX18;
